Novexel Strengthens its Scientific Advisory Board with the Appointment of Dr. Karen Bush
Novexel announced the appointment of Dr. Karen Bush to the Company’s Scientific Advisory Board (SAB). Novexel’s SAB is chaired by Dr. David Shlaes who sits on the Company’s board. Dr. Bush, who is currently Adjunct Professor at the Department of biology at Indiana University, brings extensive experience and knowledge of the anti-infectives field to Novexel’s SAB.
Dr. Bush’s scientific career in anti-infective research and development spans over three decades. During her career, Dr. Bush has held the position of Distinguished Research Fellow at Johnson & Johnson, Director of Microbial Biochemistry at the Astra Research Center, Boston, MA; Senior Research Fellow, Infectious Disease at Wyeth and Principal Investigator at the Department of Microbiology at Bristol Myers Squibb. Over this period, Dr. Bush was a member of the scientific teams that developed a portfolio of leading hospital antibiotics including levofloxacin (Levaquin), doripenem (Doribax). aztreonam (Azactam) and piperacillin-tazobactam (Zozyn). Dr. Bush received her Ph.D. from the Indiana University Chemistry Department in 1970. Moreover, Dr. Bush was elected a Fellow of the American Academy of Microbiology in 2000, in recognition of her record of scientific achievement and original contributions to microbiology.
Other news from the department people
